- NASDAQ: HTBX is set for a 7% increase on Thursday, following Wednesday's leap of the same scale.
- Speculation that Heat Biologics may receive a government grant may continue fueling the rally.
- Promising pre-clinical data in its coronavirus-vaccine candidate is keeping the stock bid.
The race to develop immunization for coronavirus vaccine is warming up – with Heat Biologics (NASDAQ: HTBX) gaining speed. The Morrisville, North Carolina based firm has yet to generate revenue – but it may receive support from Uncle Sam. The US government has been generously awarding funds to firms working on immunization to COVID-19 – including Kodak, a company that filed for Chapter 11.
Pre-revenue Heat Biologics may be the next in line and that is one of the reasons for the stock's rise. The biotechnology company reported substantial progress in its pre-clinical trial for its coronavirus vaccine candidate. Using animals, HTBX showed that subjects have developed high immunogenicity, opening the door to clinical trials.
Other firms are significantly ahead, conducting Phase 1, 2, and 3 trials. A joint venture between the University of Oxford and AstraZeneca has succeeded in generating double protection in its Phase 1/2 tests in the UK. It is set to enter Phase 3 in September.
Stateside Moderna has kicked off its Phase 3 trial among 30,000 subjects. Nevertheless, both efforts may prove futile and even if they are successful – the government is not waiting. Under Operation Warp Speed (OWS), the federal authorities have been granting money at an impressive pace indeed.
Heat Biologics could accelerate development if it receives a cash injection from the government. Hopes for such a boost are probably already impacting the stock price.
HTBX stock forecast
NASDAQ: HTBX is changing hands at around $2.40 in pre-market trading – up some 7% but still below the 52-week high of $4.07 – giving it ample room to rise. The recent trough of $2.07 serves as a support and is followed by $1.18, another resting point on the way up.
Looking ahead of the 52-week high, the $3 is another stepping stone on the way up – a psychologically significant level.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers.